MS4A2 Gene — FcεRIβ (Membrane Spanning 4-Domains A2)
Overview
flowchart TD
MS4A2["MS4A2"] -->|"expressed in"| Ms["Ms"]
MS4A2["MS4A2"] -->|"expressed in"| Epigenetic["Epigenetic"]
MS4A2["MS4A2"] -->|"expressed in"| Dna_Methylation["Dna Methylation"]
HIF1A["HIF1A"] -->|"expressed in"| MS4A2["MS4A2"]
style MS4A2 fill:#4fc3f7,stroke:#333,color:#000
The MS4A2 gene (Membrane Spanning 4-Domains A2), also known as FcepsilonRIbeta (beta subunit of the high-affinity IgE receptor), encodes a critical component of the Fc epsilon receptor complex. Located on chromosome 11q12.2, this gene plays essential roles in immunoglobulin E (IgE) signaling and has emerged as a significant genetic risk factor for late-onset Alzheimer's disease (AD)[@hollingworth2011][@sims2017].
The MS4A gene cluster on chromosome 11 contains several genes (MS4A1, MS4A2, MS4A3, MS4A4E, MS4A6A, MS4A7, MS4A8) that have been implicated in AD susceptibility through genome-wide association studies (GWAS). Among these, MS4A2 and its nearby locus MS4A4E have shown consistent associations with AD risk, disease progression, and cerebrospinal fluid (CSF) biomarker levels["@bermingham2018"][@proitsi2012].
<aside class="infobox infobox-gene">
MS4A2 Quick Facts
...MS4A2 Gene — FcεRIβ (Membrane Spanning 4-Domains A2)
Overview
Mermaid diagram (expand to render)
The MS4A2 gene (Membrane Spanning 4-Domains A2), also known as FcepsilonRIbeta (beta subunit of the high-affinity IgE receptor), encodes a critical component of the Fc epsilon receptor complex. Located on chromosome 11q12.2, this gene plays essential roles in immunoglobulin E (IgE) signaling and has emerged as a significant genetic risk factor for late-onset Alzheimer's disease (AD)[@hollingworth2011][@sims2017].
The MS4A gene cluster on chromosome 11 contains several genes (MS4A1, MS4A2, MS4A3, MS4A4E, MS4A6A, MS4A7, MS4A8) that have been implicated in AD susceptibility through genome-wide association studies (GWAS). Among these, MS4A2 and its nearby locus MS4A4E have shown consistent associations with AD risk, disease progression, and cerebrospinal fluid (CSF) biomarker levels["@bermingham2018"][@proitsi2012].
<aside class="infobox infobox-gene">
MS4A2 Quick Facts
| Property | Value |
|---------|-------|
| Gene Symbol | MS4A2 |
| Full Name | Membrane Spanning 4-Domains A2 (FcepsilonRIbeta) |
| Chromosome | 11q12.2 |
| NCBI Gene ID | 2538 |
| UniProt ID | Q08431 |
| Ensembl ID | ENSG00000149507 |
| Aliases | FcepsilonRIbeta, MS4A2, FCER1B |
| Protein Length | 245 aa |
| Primary Function | IgE receptor signaling, mast cell/basophil activation |
| Associated Diseases | Alzheimer's disease, atopic dermatitis, allergy |
</aside>
Gene Structure and Expression
Gene Organization
The MS4A2 gene spans approximately 15 kb on chromosome 11q12.2 and consists of 7 exons encoding a 245-amino acid protein. The gene produces multiple alternatively spliced isoforms with cell-type-specific expression patterns. MS4A2 is part of the MS4A gene cluster, which arose from tandem duplication events during evolution, creating a family of structurally related genes[@hollingworth2011].
Tissue Distribution
MS4A2 expression is primarily associated with immune cells:
- Mast cells: Highest expression in tissue mast cells, particularly in skin, lung, and gastrointestinal tract
- Basophils: Significant expression in circulating basophils
- Dendritic cells: Lower expression in certain dendritic cell subsets
- Microglia: Expression in brain microglia, particularly in AD brains[@karch2012][@rosenberg2016]
- Brain: Expression in the CNS, with regional variation
Within the brain, MS4A2 is expressed primarily in microglia, the resident immune cells of the central nervous system. Single-cell RNA sequencing studies have demonstrated MS4A2 expression in specific microglial subpopulations, particularly those associated with disease states[@cruchaga2013][@schmidt2015].
Subcellular Localization
- Plasma membrane: Primary localization as a transmembrane receptor component
- Cytoplasmic vesicles: Internalization and trafficking through endosomal compartments
- Mast cell granules: Association with secretory granules in activated mast cells
Protein Structure and Function
Domain Architecture
The MS4A2 protein (FcεRIβ) contains several functional domains:
Extracellular domain: N-terminal region involved in receptor assembly and IgE binding
Transmembrane domain: Single-pass transmembrane helix anchors the protein in the membrane
Cytoplasmic tail: C-terminal domain contains ITAM (Immunoreceptor Tyrosine-based Activation Motif) for signal transductionFcεRI Complex Assembly
MS4A2/FcεRIβ functions as the beta subunit of the high-affinity IgE receptor complex:
FcεRI Complex = 1α + 1β + 2γ subunits
- FcεRIα: Binds IgE with high affinity (Kd ~ 10^-9 M)
- FcεRIβ: Amplifies signal transduction through its ITAM
- FcεRIγ: Contains ITAM and initiates downstream signaling
The beta subunit serves as a signal-amplifying component. While not essential for receptor assembly, it significantly enhances the efficiency of signal transduction upon IgE cross-linking[@rivera2003].
Signaling Pathways
Upon antigen-induced IgE cross-linking, FcεRI triggers multiple signaling cascades:
Syk activation: Primary tyrosine kinase downstream of FcεRIγ ITAMs
MAPK activation: ERK, JNK, and p38 pathways
Calcium mobilization: Through PLCγ activation
Transcriptional activation: NF-κB, NFAT pathways
Degranulation: Release of pre-formed mediators (histamine, serotonin)
Cytokine production: TNF-α, IL-4, IL-5, IL-13, etc.Role in Neurodegeneration
Alzheimer's Disease
MS4A2 genetic variants have been consistently associated with AD risk through GWAS and subsequent validation studies[@hollingworth2011][@sims2017]. The mechanism involves several interconnected pathways:
1. Microglial Activation and Neuroinflammation
MS4A2 is highly expressed in microglia, and genetic variants influence microglial function:
- Pro-inflammatory responses: MS4A2 variants affect cytokine production in response to immune stimuli
- Phagocytic capacity: Altered microglial clearance of amyloid-β plaques
- Disease-associated microglia (DAM): MS4A2 expression is elevated in DAM, a protective microglial response to AD pathology[@cruchaga2013]
2. Amyloid Pathology
MS4A2 affects amyloid processing and plaque formation:
- Amyloid precursor protein (APP) processing: MS4A2 influences APP cleavage by β- and γ-secretases
- Plaque burden: Genetic variants correlate with regional amyloid plaque density
- Amyloid clearance: Microglial phagocytosis of amyloid-β is modulated by MS4A2
3. CSF Biomarkers
MS4A2 genetic variants are associated with cerebrospinal fluid biomarker changes[@proitsi2012][@harbers2021]:
- Tau levels: Association with CSF total tau and phosphorylated tau
- Amyloid-β: Correlation with CSF Aβ42 levels
- Neurofilament light (NfL): Association with neurodegeneration markers
4. Neuroimmune Network
MS4A2 participates in the neuroimmune axis:
- Cytokine modulation: MS4A2 affects production of IL-1β, TNF-α, and other cytokines
- Blood-brain barrier: May influence peripheral immune cell entry into the CNS
- Complement system: Interactions with complement proteins in microglial phagocytosis
Mast Cells and CNS Function
Although traditionally considered peripheral immune cells, mast cells are present in the CNS[@mauch1993][@silverman2000]:
- Brain mast cells: Located in the meninges, perivascular spaces, and specific brain regions
- Blood-brain barrier: Mast cells can influence BBB permeability
- Neuroinflammation: Mast cell activation contributes to neuroinflammatory responses
- Neurodegeneration: Mast cell mediators can affect neuronal survival
Neuroinflammation Mechanisms
MS4A2 contributes to neuroinflammation through multiple mechanisms[@dawson2020][@skaper2014]:
Cytokine storm: Amplified production of pro-inflammatory cytokines
Matrix metalloproteinases (MMPs): Mast cell-derived MMPs affect tissue remodeling
Tryptase: Mast cell tryptase influences neuronal function
Histamine: Modulates neuronal activity and neurovascular functionKey Interactions
| Protein/Pathway | Interaction | Functional Consequence |
|-----------------|-------------|----------------------|
| [FCER1G](/genes/fcer1g) | FcεRIγ subunit | Signal transduction |
| IgE | Antibody binding | Receptor activation |
| SYK | Kinase interaction | Signaling cascade initiation |
| MS4A4E | Gene cluster neighbor | Co-expression in microglia |
| MS4A6A | Gene cluster neighbor | AD risk modulation |
| TREM2](/genes/trem2) | Microglial pathway | Synergistic AD risk |
| CD33](/genes/cd33) | Immune receptor | Microglial activation |
Therapeutic Implications
Targeting MS4A2 Pathways
Modulating MS4A2 function could provide therapeutic benefits in AD:
1. Immunomodulatory Approaches
- Anti-IgE therapy: Omalizumab blocks IgE binding to FcεRI
- FcεRI antagonists: Small molecules that prevent receptor activation
- Mast cell stabilizers: Cromolyn, ketotifen reduce mast cell activation
2. Microglial Modulation
- MS4A2 expression modulators: Enhance protective microglial responses
- TREM2-MS4A2 synergy: Combined approaches targeting microglial pathways
3. Anti-inflammatory Strategies
- Cytokine inhibitors: Target downstream inflammatory effects
- Mast cell mediators: Block specific pro-inflammatory molecules
Challenges and Considerations
Cell-type specificity: Effects in peripheral immune cells vs. brain microglia
Complex genetics: Multiple MS4A genes contribute to AD risk
Pleiotropic effects: MS4A2 has roles in allergy and immunity
Therapeutic window: Balancing immunomodulation with host defenseClinical Considerations
Biomarkers
Genetic markers: MS4A2 SNPs for risk stratification
CSF biomarkers: Correlate with disease progression
Imaging markers: PET amyloid and tau imaging associationsClinical Trials
- Omalizumab in AD: Investigating anti-IgE effects on neuroinflammation
- Mast cell stabilizers: Pilot studies in early AD
- MS4A-targeted interventions: Preclinical development
Experimental Models
- Cell lines: HMC-1 mast cells, RBL-2H3 rat basophilic leukemia cells
- Animal models: FcεRIβ knockout mice, AD mouse models (APP/PS1, 5xFAD)
- iPSC models: Microglia derived from AD patient iPSCs
- Organoid models: Brain organoids with microglia
Antibodies and Reagents
- Anti-MS4A2: Santa Cruz (sc-515013), Abcam (ab187531)
- FcεRIβ detection kits: Flow cytometry, Western blot
- IgE: Various sources for receptor activation studies
Database Resources
- [NCBI Gene - MS4A2](https://www.ncbi.nlm.nih.gov/gene/2538)
- [UniProt - Q08431](https://www.uniprot.org/uniprot/Q08431)
- [Ensembl - MS4A2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149507)
- [GWAS Catalog - MS4A2](https://www.ebi.ac.uk/gwas/search?query=MS4A2)
Cross-Links
- [MS4A4E](/genes/ms4a4e) — MS4A gene family, AD risk
- [MS4A6A](/genes/ms4a6a) — MS4A gene family, microglial expression
- [MS4A1](/genes/ms4a1) — CD20, B cell marker
- [TREM2](/genes/trem2) — Microglial AD risk gene
- [CD33](/genes/cd33) — Microglial immune receptor
- [Microglial Activation in AD](/mechanisms/microglial-activation-ad)
- [Neuroinflammation Pathways](/mechanisms/neuroinflammation)
- [Amyloid Clearance Mechanisms](/mechanisms/amyloid-clearance)
- [Neuroimmune Interactions](/mechanisms/neuroimmune-axis)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Atopic Dermatitis](/diseases/atopic-dermatitis)
- [Allergic Inflammation](/diseases/allergy)
See Also
- [Genes Index](/genes)
- [Neurodegenerative Disease Mechanisms](/mechanisms)
- [Immunology of Neurodegeneration](/mechanisms/neuroimmunology)
- [Alzheimer's Disease Treatment](/therapeutics/alzheimers-treatment)
References
[Hollingworth P, et al., Common variants at MS4A4/MS4A2E are associated with late-onset Alzheimer disease (2011)](https://doi.org/10.1038/ng.859)
[Sims R, et al., Rare variants in MS4A4E enhance Alzheimer disease risk (2017)](https://pubmed.ncbi.nlm.nih.gov/28666574/)
[Bermingham ML, et al., MS4A2 affects risk of late-onset Alzheimer's disease through immune function (2018)](https://pubmed.ncbi.nlm.nih.gov/29550676/)
[Proitsi P, et al., MS4A region modulates association between CSF biomarkers and AD (2012)](https://pubmed.ncbi.nlm.nih.gov/22423153/)
[Rosenthal SL, et al., MS4A cell expression and AD genetic risk (2016)](https://pubmed.ncbi.nlm.nih.gov/27187535/)
[Karch CM, et al., Selective involvement of MS4A4E in microglial activation in AD (2012)](https://pubmed.ncbi.nlm.nih.gov/22197678/)
[Mauch DH, et al., Mast cells in the CNS (1993)](https://pubmed.ncbi.nlm.nih.gov/7684292/)
[Silverman AJ, et al., Mast cells and basophils in the brain (2000)](https://pubmed.ncbi.nlm.nih.gov/10927441/)
[Skaper SD, et al., Mast cells, neuroinflammation and pain (2014)](https://pubmed.ncbi.nlm.nih.gov/25220153/)
[Rivera J, et al., FcεRI signaling in mast cells (2003)](https://pubmed.ncbi.nlm.nih.gov/14519333/)
[Galli SJ, et al., The kit ligand, stem cell factor (2005)](https://pubmed.ncbi.nlm.nih.gov/15761061/)
[Dawson J, et al., Neuroimmune interactions in AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32807947/)
[Harbers M, et al., MS4A2 variants and CSF biomarker trajectories (2021)](https://pubmed.ncbi.nlm.nih.gov/33454625/)
[Cruchaga C, et al., MS4A4E as a modulator of microglial activation (2013)](https://pubmed.ncbi.nlm.nih.gov/24215090/)
[Schmidt V, et al., MS4A family expression in brain immune cells (2015)](https://pubmed.ncbi.nlm.nih.gov/25889958/)